DNA methylation of tumor-suppressor miRNA genes in chronic lymphocytic leukemia

Papers of special note have been highlighted as: • of interest

References

• 1 Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N. Engl. J. Med. 352, 804–815 (2005).
  Medline CASGoogle Scholar
• 2 Crespo M, Bosch F, Villamor N et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N. Engl. J. Med. 348, 1764–1775 (2003).
  Medline CASGoogle Scholar
• 3 Oscier DG, Gardiner AC, Mould SJ et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 100, 1177–1184 (2002).
  Medline CASGoogle Scholar
• 4 Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94, 1848–1854 (1999).
  Medline CASGoogle Scholar
• 5 Kröber A, Seiler T, Benner A et al. VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100, 1410–1416 (2002).
  Medline CASGoogle Scholar
• 6 Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping. Leukemia 21, 2442–2451 (2007).
  Medline CASGoogle Scholar
• 7 Döhner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343, 1910–1916 (2000).
  Medline CASGoogle Scholar
• 8 Munk Pedersen I, Reed J. Microenvironmental interactions and survival of CLL B-cells. Leuk. Lymphoma 45, 2365–2372 (2004).
  Medline CASGoogle Scholar
• 9 Caligaris-Cappio F, Bertilaccio M, Scielzo C. How the microenvironment wires the natural history of chronic lymphocytic leukemia. Semin. Cancer Biol. 24, 43–48 (2014).
  MedlineGoogle Scholar
• 10 Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 111, 846–855 (2008).
  Medline CASGoogle Scholar
• 11 Pleyer L, Egle A, Hartmann TN, Greil R. Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat. Rev. Clin. Oncol. 6, 405–418 (2009).
  Medline CASGoogle Scholar
• 12 Lu D, Zhao Y, Tawatao R et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 101, 3118–3123 (2004).
  Medline CASGoogle Scholar
• 13 Furman RR, Asgary Z, Mascarenhas JO, Liou H-C, Schattner EJ. Modulation of NF-κB activity and apoptosis in chronic lymphocytic leukemia B cells. J. Immunol. 164, 2200–2206 (2000).
  Medline CASGoogle Scholar
• 14 Cuni S, Perez-Aciego P, Perez-Chacon G et al. A sustained activation of PI3K/NF-κB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 18, 1391–1400 (2004).
  Medline CASGoogle Scholar
• 15 Puente XS, Pinyol M, Quesada V et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475, 101–105 (2011).
  Medline CASGoogle Scholar
• 16 Quesada V, Conde L, Villamor N et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nature Genet. 44, 47–52 (2012).
  CASGoogle Scholar
• 17 Fabbri G, Rasi S, Rossi D et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J. Exp. Med. 208, 1389–1401 (2011).
  Medline CASGoogle Scholar
• 18 Wang L, Lawrence MS, Wan Y et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. Med. 365, 2497–2506 (2011).
  Medline CASGoogle Scholar
• 19 Kulis M, Heath S, Bibikova M et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nature Genet. 44, 1236–1242 (2012).
  Medline CASGoogle Scholar
• 20 Chim CS, Liang R, Kwong YL. Hypermethylation of gene promoters in hematological neoplasia. Hematol. Oncol. 20, 167–176 (2002).
  Medline CASGoogle Scholar
• 21 Jones PA. Cancer: death and methylation. Nature 409, 141–144 (2001).
  Medline CASGoogle Scholar
• 22 Robertson KD. DNA methylation and human disease. Nat. Rev. Genet. 6, 597–610 (2005).
  Medline CASGoogle Scholar
• 23 Esteller M. Epigenetics in cancer. N. Engl. J. Med. 358, 1148–1159 (2008).
  Medline CASGoogle Scholar
• 24 Jones PA, Baylin SB. The epigenomics of cancer. Cell 128, 683–692 (2007).
  Medline CASGoogle Scholar
• 25 Portela A, Esteller M. Epigenetic modifications and human disease. Nat. Biotechnol. 28, 1057–1068 (2010).
  Medline CASGoogle Scholar
• 26 Laird PW. Cancer epigenetics. Hum. Mol. Genet. 14, R65–R76 (2005).
  Medline CASGoogle Scholar
• 27 Knudson AG. Karnofsky Memorial Lecture. Hereditary cancer: theme and variations. J. Clin. Oncol. 15, 3280–3287 (1997).
  Medline CASGoogle Scholar
• 28 Thiagalingam S, Foy RL, Cheng K-H, Lee HJ, Thiagalingam A, Ponte JF. Loss of heterozygosity as a predictor to map tumor suppressor genes in cancer: molecular basis of its occurrence. Curr. Opin. Oncol. 14, 65–72 (2002).
  Medline CASGoogle Scholar
• 29 Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2, 594–604 (2002).
  Medline CASGoogle Scholar
• 30 Yue Z, Jin S, Yang C, Levine AJ, Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc. Natl Acad. Sci. USA 100, 15077–15082 (2003).
  Medline CASGoogle Scholar
• 31 Berger AH, Knudson AG, Pandolfi PP. A continuum model for tumour suppression. Nature 476, 163–169 (2011).
  Medline CASGoogle Scholar
• 32 Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum. Mol. Genet. 16, R50–R59 (2007).
  Medline CASGoogle Scholar
• 33 Chim CS, Fung TK, Wong KF, Lau JS, Law M, Liang R. Methylation of INK4 and CIP/KIP families of cyclin-dependent kinase inhibitor in chronic lymphocytic leukaemia in Chinese patients. J. Clin. Pathol. 59, 921–926 (2006).
  Medline CASGoogle Scholar
• 34 Chim CS, Pang R, Fung TK, Choi CL, Liang R. Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia 21, 2527–2536 (2007).
  Medline CASGoogle Scholar
• 35 Chim CS, Fung TK, Cheung WC, Liang R, Kwong YL. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood 103, 4630–4635 (2004).
  Medline CASGoogle Scholar
• 36 Gonzalez-Zulueta M, Bender CM, Yang AS et al. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 55, 4531–4535 (1995).
  Medline CASGoogle Scholar
• 37 Raval A, Tanner SM, Byrd JC et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 129, 879–890 (2007).
  Medline CASGoogle Scholar
• 38 Chen SS, Claus R, Lucas DM et al. Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL. Blood 117, 862–871 (2011).
  Medline CASGoogle Scholar
• 39 Chim CS, Fung TK, Wong K, Lau J, Liang R. Frequent DAP kinase but not p14 or Apaf-1 hypermethylation in B-cell chronic lymphocytic leukemia. J. Hum. Genet. 51, 832–838 (2006).
  Medline CASGoogle Scholar
• 40 Chim CS, Pang R, Liang R. Epigenetic dysregulation of the Wnt signalling pathway in chronic lymphocytic leukaemia. J. Clin. Pathol. 61, 1214–1219 (2008).
  Medline CASGoogle Scholar
• 41 Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 136, 215–233 (2009).
  Medline CASGoogle Scholar
• 42 Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297 (2004).
  Medline CASGoogle Scholar
• 43 Calin GA, Sevignani C, Dumitru CD et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl Acad. Sci. USA 101, 2999–3004 (2004).• First study to show that more than 50% of miRNA genes are localized to cancer-associated genomic regions, and hence an important role in the pathogenesis of cancer.
  Medline CASGoogle Scholar
• 44 Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 10, 704–714 (2009).
  Medline CASGoogle Scholar
• 45 Chen C-Z. MicroRNAs as oncogenes and tumor suppressors. N. Engl. J. Med. 353, 1768–1771 (2005).
  Medline CASGoogle Scholar
• 46 Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 99, 15524–15529 (2002).• First study to describe dysregulation of miRNAs in cancer, illustrating downregulation of miR-15 and miR-16 inherent with 13q14 deletion is pivotal to chronic lymphocytic leukemia (CLL) leukemogenesis.
  Medline CASGoogle Scholar
• 47 Cimmino A, Calin G, Fabbri M et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl Acad. Sci. USA 102, 13944–13949 (2005).
  Medline CASGoogle Scholar
• 48 Klein U, Lia M, Crespo M et al. The DLEU2/miR-15a/16–1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17, 28–40 (2010).
  Medline CASGoogle Scholar
• 49 Pekarsky Y, Palamarchuk A, Maximov V et al. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc. Natl Acad. Sci. USA 105, 19643–19648 (2008).
  Medline CASGoogle Scholar
• 50 Bichi R, Shinton SA, Martin ES et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc. Natl Acad. Sci. USA 99, 6955–6960 (2002).
  Medline CASGoogle Scholar
• 51 Pekarsky Y, Santanam U, Cimmino A et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 66, 11590–11593 (2006).
  Medline CASGoogle Scholar
• 52 Calin GA, Ferracin M, Cimmino A et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 353, 1793–1801 (2005).• First paper showing an important signature of 13 miRNAs differentially expressed between high-risk and low-risk of CLL patients.
  Medline CASGoogle Scholar
• 53 Santanam U, Zanesi N, Efanov A et al. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc. Natl Acad. Sci. USA 107, 12210–12215 (2010).
  Medline CASGoogle Scholar
• 54 Visone R, Veronese A, Rassenti LZ et al. miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood 118, 3072–3079 (2011).
  Medline CASGoogle Scholar
• 55 Zhu D-X, Zhu W, Fang C et al. miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis 33, 1294–1301 (2012).
  Medline CASGoogle Scholar
• 56 Calin GA, Cimmino A, Fabbri M et al. MiR-15a and miR-16–1 cluster functions in human leukemia. Proc. Natl Acad. Sci. USA 105, 5166–5171 (2008).
  Medline CASGoogle Scholar
• 57 Fabbri M, Bottoni A, Shimizu M et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA 305, 59–67 (2011).
  Medline CASGoogle Scholar
• 58 Li S, Moffett HF, Lu J et al. MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells. PLoS ONE 6, e16956 (2011).
  Medline CASGoogle Scholar
• 59 Calin G, Liu C, Sevignani C et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc. Natl Acad. Sci. USA 101, 11755–11760 (2004).
  Medline CASGoogle Scholar
• 60 Fulci V, Chiaretti S, Goldoni M et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 109, 4944–4951 (2007).
  Medline CASGoogle Scholar
• 61 Visone R, Rassenti LZ, Veronese A et al. Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood 114, 3872–3879 (2009).
  Medline CASGoogle Scholar
• 62 Wang LQ, Liang R, Chim CS. Methylation of tumor suppressor microRNAs: lessons from lymphoid malignancies. Expert Rev. Mol. Diagn. 12, 10 (2012).
  CASGoogle Scholar
• 63 Pallasch CP, Patz M, Park YJ et al. miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood 114, 3255–3264 (2009).• A study to demonstrate a pathological link between a cluster of downregulated miRNAs, many of which account for overexpression of the oncogenic PLAG1 in CLL.
  Medline CASGoogle Scholar
• 64 Baer C, Claus R, Frenzel LP et al. Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia. Cancer Res. 72, 3775–3785 (2012).• A study to show a panel of methylation-mediated dysregulated miRNAs could be derived from combined analysis of miRNA expression profiling and genome-wide methylation profiling in CLL.
  Medline CASGoogle Scholar
• 65 Saini S, Majid S, Shahryari V et al. miRNA-708 control of CD44+ prostate cancer-initiating cells. Cancer Res. 72, 3618–3630 (2012).
  Medline CASGoogle Scholar
• 66 Chen SS, Raval A, Johnson AJ et al. Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 106, 13433–13438 (2009).
  Medline CASGoogle Scholar
• 67 Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 17, 193–199 (2009).
  MedlineGoogle Scholar
• 68 Yamakuchi M, Lowenstein CJ. MiR-34, SIRT1 and p53. Cell Cycle 8, 712–715 (2009).
  Medline CASGoogle Scholar
• 69 Zenz T, Eichhorst B, Busch R et al. TP53 mutation and survival in chronic lymphocytic leukemia. J. Clin. Oncol. 28, 4473–4479 (2010).
  MedlineGoogle Scholar
• 70 Lujambio A, Calin GA, Villanueva A et al. A microRNA DNA methylation signature for human cancer metastasis. Proc. Natl Acad. Sci. USA 105, 13556–13561 (2008).• A good example to identify aberrant methylated miRNAs implicated in cancer metastasis development by the strategy of treating metastasis cancer cells with a DNA-demethylating agent followed by microarray analysis.
  Medline CASGoogle Scholar
• 71 Gallardo E, Navarro A, Viñolas N et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 30, 1903–1909 (2009).
  Medline CASGoogle Scholar
• 72 Wong KY, Yu L, Chim CS. DNA methylation of tumor suppressor miRNA genes: a lesson from the miR-34 family. Epigenomics 3, 83–92 (2011).
  CASGoogle Scholar
• 73 Vogt M, Munding J, Grüner M et al. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch. 458, 313–322 (2011).
  MedlineGoogle Scholar
• 74 Lodygin D, Tarasov V, Epanchintsev A et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7, 2591–2600 (2008).
  Medline CASGoogle Scholar
• 75 Chim CS, Wong KY, Qi Y et al. Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis 31, 745–750 (2010).
  Medline CASGoogle Scholar
• 76 Toyota M, Suzuki H, Sasaki Y et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 68, 4123 (2008).
  Medline CASGoogle Scholar
• 77 Tsai KW, Wu CW, Hu LY et al. Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. Int. J. Cancer 129, 2600–2610 (2011).
  Medline CASGoogle Scholar
• 78 Corney DC, Hwang CI, Matoso A et al. Frequent downregulation of miR-34 family in human ovarian cancers. Clin. Cancer Res. 16, 1119–1128 (2010).
  Medline CASGoogle Scholar
• 79 Wang LQ, Kwong YL, Wong KF et al. Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia. J. Transl. Med. 12, 52 (2014).
  Medline CASGoogle Scholar
• 80 Cardinaud B, Moreilhon C, Marcet B et al. miR-34b/miR-34c: a regulator of TCL1 expression in 11q- chronic lymphocytic leukaemia. Leukemia 23, 2174–2177 (2009).
  Medline CASGoogle Scholar
• 81 Pigazzi M, Manara E, Baron E, Basso G. miR-34b targets cyclic AMP–responsive element binding protein in acute myeloid leukemia. Cancer Res. 69, 2471–2478 (2009).
  Medline CASGoogle Scholar
• 82 Wong KY, Liang R, So CC, Jin DY, Costello JF, Chim CS. Epigenetic silencing of MIR203 in multiple myeloma. Br. J. Haematol. 154, 569–578 (2011).
  Medline CASGoogle Scholar
• 83 Deneberg S, Kanduri M, Ali D et al. microRNA-34b/c on chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia. Epigenetics 9, 0–1 (2014).
  CASGoogle Scholar
• 84 Ma L, Young J, Prabhala H et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol. 12, 247–256 (2010).
  Medline CASGoogle Scholar
• 85 Tsai KW, Liao YL, Wu CW et al. Aberrant hypermethylation of miR-9 genes in gastric cancer. Epigenetics 6, 1189 (2011).
  Medline CASGoogle Scholar
• 86 Schraivogel D, Weinmann L, Beier D et al. CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells. EMBO J. 30, 4309–4322 (2011).
  Medline CASGoogle Scholar
• 87 Nass D, Rosenwald S, Meiri E et al. MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol. 19, 375–383 (2009).
  Medline CASGoogle Scholar
• 88 Heller G, Weinzierl M, Noll C et al. Genome-wide miRNA expression profiling identifies miR-9–3 and miR-193a as targets for DNA methylation in non-small cell lung cancers. Clin. Cancer Res. 18, 1619–1629 (2012).
  Medline CASGoogle Scholar
• 89 Zhang H, Qi M, Li S et al. microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells. Mol. Cancer Ther. 11, 1454–1466 (2012).
  MedlineGoogle Scholar
• 90 Guo LM, Pu Y, Han Z et al. MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-κB1. FEBS J. 276, 5537–5546 (2009).
  Medline CASGoogle Scholar
• 91 Wang LQ, Kwong YL, Kho CSB et al. Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia-implications on constitutive activation of NFκB pathway. Mol. Cancer 12, 173 (2013).
  MedlineGoogle Scholar
• 92 Anderlind C, Spira A, Cardoso WV, Lü J. miR-129 regulates cell proliferation by downregulating Cdk6 expression. Cell Cycle 9, 1809–1818 (2010).
  MedlineGoogle Scholar
• 93 Bandres E, Agirre X, Bitarte N et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int. J. Cancer 125, 2737–2743 (2009).
  Medline CASGoogle Scholar
• 94 Huang Y, Liu J, Deatherage D et al. Epigenetic repression of microRNA-129–2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res. 69, 9038–9046 (2009).
  Medline CASGoogle Scholar
• 95 Wong KY, Yim RLH, Kwong YL et al. Epigenetic inactivation of the MIR129–2 in hematological malignancies. J. Hematol. Oncol. 6, 16 (2013).
  Medline CASGoogle Scholar
• 96 Agirre X, Vilas-Zornoza A, Jimenez-Velasco A et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res. 69, 4443–4453 (2009).
  Medline CASGoogle Scholar
• 97 Furuta M, Kozaki K-I, Tanaka S, Arii S, Imoto I, Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 31, 766–776 (2010).
  Medline CASGoogle Scholar
• 98 Wilting SM, Van Boerdonk RaA, Henken FE et al. Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol. Cancer 9, 167 (2010).
  MedlineGoogle Scholar
• 99 Silber J, Lim DA, Petritsch C et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med. 6, 14 (2008).
  MedlineGoogle Scholar
• 100 Xia J, Wu Z, Yu C et al. miR-124 inhibits cell proliferation in gastric cancer through down-regulation of SPHK1. J. Pathol. 227, 470–480 (2012).
  Medline CASGoogle Scholar
• 101 Wang P, Chen L, Zhang J et al. Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene 33, 514–524 (2013).
  Medline CASGoogle Scholar
• 102 Wong KY, So CC, Loong F et al. Epigenetic inactivation of the miR-124–1 in haematological malignancies. PLoS ONE 6, e19027 (2011).
  Medline CASGoogle Scholar
• 103 Bueno MJ, Pérez De Castro I, Gómez De Cedrón M et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 13, 496–506 (2008).
  Medline CASGoogle Scholar
• 104 Chim CS, Wong KY, Leung CY et al. Epigenetic inactivation of the hsa-miR-203 in haematological malignancies. J. Cell Mol. Med. 15, 2760–2767 (2011).
  Medline CASGoogle Scholar
• 105 Stamatopoulos B, Meuleman N, Haibe-Kains B et al. microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood 113, 5237–5245 (2009).
  Medline CASGoogle Scholar
• 106 Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59, 67–70 (1999).
  Medline CASGoogle Scholar
• 107 Mori T, O'Day SJ, Umetani N et al. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J. Clin. Oncol. 23, 9351–9358 (2005).
  Medline CASGoogle Scholar
• 108 Zhang YJ, Wu HC, Shen J et al. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin. Cancer Res. 13, 2378–2384 (2007).
  Medline CASGoogle Scholar
• 109 Blum KA, Liu Z, Lucas DM et al. Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation. Br. J. Haematol. 150, 189–195 (2010).
  Medline CASGoogle Scholar
• 110 Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. Cancer Discov. 1, 391–407 (2011).
  Medline CASGoogle Scholar
• 111 Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat. Rev. Genet. 10, 155–159 (2009).
  Medline CASGoogle Scholar
• 112 Esteller M. Non-coding RNAs in human disease. Nat. Rev. Genet. 12, 861–874 (2011).
  Medline CASGoogle Scholar
• 113 Lee K-H, Lotterman C, Karikari C et al. Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology 9, 293–301 (2009).
  Medline CASGoogle Scholar